Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Adamas Pharmaceuticals Inc.
Headquarters: Emeryville, CA, United States of America
Website: N/A
Year Founded: 2000
Status: Acquired
BioCentury | Oct 10, 2023
Management Tracks
Amgen veteran Lenz named head of R&D at Neumora
Plus: Eaton leaving Editas as CTO, CBO and updates from Poseida, Zevra, Pheon, Lexicon and more
BioCentury | Jun 13, 2023
Management Tracks
Patni becomes chief of R&D at Reata
Plus: Reilly named CEO at Damona, and updates from Akebia, Generate, Jasper and more
BioCentury | Sep 29, 2022
Management Tracks
Kevin Bunker promoted to CSO at Zentalis
Plus Fonck becomes partner at Pureos, and updates from 4D Molecular, Gandeeva, Code and more
BioCentury | Sep 21, 2022
Management Tracks
New CEOs at Scholar Rock, Neuway, NeuVasQ and ProLynx
Plus Serono’s Maria Rivas joins Pfizer, and updates from
BioCentury | Aug 4, 2022
Management Tracks
Sanofi’s Lih-Ling Lin joins PharmaEssentia as CSO
Plus Hunder becomes CMO at ProfoundBio, and updates from Nurix, Sanofi and Nucleai
BioCentury | Apr 20, 2022
Management Tracks
New CEOs at eGenesis, Fore and Cerevance
Plus Ramanan joins Turnstone as CFO, updates from Camp4, ImmPact, Akoya and more
BioCentury | Oct 12, 2021
Product Development
Oct. 11 Quick Takes: Supernus diversifies CNS portfolio with Adamas acquisition
Plus: Idorsia’s miss, Evotec, Protagonist, Enzyvant and Chance
BioCentury | Feb 2, 2021
Product Development
Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas
Immunovant Inc. (NASDAQ:IMVT) lost 42% to $25.08 on Tuesday after announcing it was pausing trials of anti-FCRN mAb IMVT-1401 (batoclimab) due to elevated total cholesterol and LDL signals in the
BioCentury | Jan 8, 2020
Company News
Management tracks: Fred Hutch taps BMS CSO Lynch; plus GSK, Rubius, Provention, Antengene, Revitope, Compugen, Wellington, Adamas, Arcturus and Turnstone
BioCentury | Apr 6, 2018
Finance
Smid-cap smorgasbord
Buysiders like 2Q cancer catalysts, rare diseases and small- to mid-cap milestones
Items per page:
1 - 10 of 65